

## Appendix: Tables

1.	Sales January to June 2019 and 2018 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2019 and 2018.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth HY 2019 vs. HY 2018.....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth HY 2019 vs. HY 2018 .....	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2019 vs. HY 2018 .....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe .....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International* .....	11
11.	Roche Group consolidated income statement for the six months ended 30 June 2019.....	12
12.	Roche Group core results reconciliation – Half Year 2019 .....	13
13.	Divisional core results reconciliation – Half Year 2019.....	14
14.	Roche Group consolidated balance sheet .....	15
15.	Roche Group consolidated statement of cash flows .....	16

## 1. Sales January to June 2019 and 2018

CHF millions	Six months ended 30 June		% change	
	2019	2018	At CER	In CHF
Pharmaceuticals Division	24,194	21,847	10	11
United States	13,370	11,378	14	18
Europe	4,221	4,528	-4	-7
Japan	1,988	1,781	9	12
International*	4,615	4,160	17	11
Diagnostics Division	6,275	6,264	2	0
Roche Group	30,469	28,111	9	8

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2019 and 2018

CHF millions	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018
Pharmaceuticals Division	11,175	7	10,855	7	11,265	8	11,927	10	12,267	11
United States	5,862	15	5,814	12	6,041	14	6,623	14	6,747	13
Europe	2,241	-8	2,079	-7	2,086	-6	2,101	-6	2,120	-2
Japan	930	0	919	0	1,001	-5	941	7	1,047	12
International*	2,142	6	2,043	14	2,137	14	2,262	17	2,353	16
Diagnostics Division	3,353	7	3,114	6	3,501	10	2,899	1	3,376	4
Roche Group	14,528	7	13,969	7	14,766	9	14,826	8	15,643	9

\*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

### 3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth HY 2019 vs. HY 2018

Top-selling pharmaceuticals January - June 2019	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	3,659	7	1,630	9	920	2	424	3	685	13
MabThera/Rituxan	3,339	-4	2,281	4	323	-36	58	-46	677	2
Herceptin	3,264	-9	1,509	-2	568	-45	123	-2	1,064	21
Perjeta	1,755	34	788	22	541	28	120	87	306	77
Ocrevus	1,735	63	1,456	50	211	179	-	-	68	204
Actemra/RoActemra	1,135	8	460	8	355	6	188	12	132	13
Xolair	972	1	972	1	-	-	-	-	-	-
Lucentis	928	10	928	10	-	-	-	-	-	-
Tecentriq	782	141	508	124	134	129	75	386	65	173
Activase/TNKase	686	2	661	2	-	-	-	-	25	-2

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth HY 2019 vs. HY 2018

New products January - June 2019	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	127	1	84	7	29	-20	-	-	14	22
Perjeta	1,755	34	788	22	541	28	120	87	306	77
Kadcyla	636	33	278	51	204	14	40	11	114	48
Gazyva	241	36	110	14	80	31	21	-	30	59
Esbriet	532	11	374	8	128	16	-	-	30	44
Cotellic	30	-4	6	-33	17	-3	-	-	7	46
Alecensa	421	50	149	9	96	167	105	19	71	220
Tecentriq	782	141	508	124	134	129	75	386	65	173
Ocrevus	1,735	63	1,456	50	211	179	-	-	68	204
Hemlibra	535	**	381	**	63	**	82	**	9	-
Xofluza	6	-	6	-	-	-	-	-	-	-
Polivy	2	-	2	-	-	-	-	-	-	-

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2019 vs. HY 2018

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	3,659	7	1,630	9	920	2	424	3	685	13
MabThera/Rituxan	3,339	-4	2,281	4	323	-36	58	-46	677	2
Herceptin	3,264	-9	1,509	-2	568	-45	123	-2	1,064	21
Perjeta	1,755	34	788	22	541	28	120	87	306	77
Ocrevus	1,735	63	1,456	50	211	179	-	-	68	204
Actemra/RoActemra	1,135	8	460	8	355	6	188	12	132	13
Xolair	972	1	972	1	-	-	-	-	-	-
Lucentis	928	10	928	10	-	-	-	-	-	-
Tecentriq	782	141	508	124	134	129	75	386	65	173
Activase/TNKase	686	2	661	2	-	-	-	-	25	-2
Kadcyla	636	33	278	51	204	14	40	11	114	48
Hemlibra	535	**	381	**	63	**	82	**	9	-
Esbriet	532	11	374	8	128	16	-	-	30	44
Alecensa	421	50	149	9	96	167	105	19	71	220
Pulmozyme	371	3	253	3	68	6	-	-	50	2
CellCept	325	-1	43	-23	87	0	42	7	153	6
Mircera	282	13	-	-	34	-9	100	3	148	28
Gazyva	241	36	110	14	80	31	21	-	30	59
Tamiflu	227	-29	31	-82	41	92	72	-6	83	46
Xeloda	216	1	15	-18	8	-7	43	-23	150	14

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018
Avastin	1,778	1	1,690	6	1,741	5	1,798	9	1,861	6
MabThera/Rituxan	1,741	-11	1,656	-7	1,642	-6	1,694	-3	1,645	-5
Herceptin	1,850	2	1,683	1	1,675	-3	1,666	-6	1,598	-12
Perjeta	700	28	699	27	761	35	868	41	887	29
Ocrevus	561	195	633	104	680	83	836	67	899	59
Actemra/RoActemra	550	13	529	9	582	14	534	6	601	10
Xolair	486	14	498	9	486	12	469	1	503	2
Lucentis	425	27	413	2	428	47	457	11	471	9
Tecentriq	181	44	204	71	248	89	336	135	446	146
Activase/TNKase	329	10	317	1	315	4	362	7	324	-3
Kadcyla	249	11	244	8	251	7	291	24	345	42
Hemlibra	34	-	56	-	111	*	219	*	316	*
Esbriet	250	15	267	21	292	26	250	10	282	13
Alecensa	160	98	158	62	200	69	196	61	225	41
Pulmozyme	188	6	180	1	202	3	182	6	189	0
CellCept	175	-4	175	4	161	-9	163	4	162	-4
Mircera	128	4	150	16	134	-4	142	16	140	10
Gazyva	93	38	104	51	109	44	115	35	126	38
Tamiflu	28	-75	13	-63	45	-67	179	-40	48	110
Xeloda	114	-11	110	-2	101	-8	108	5	108	-2

\* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018
Avastin	743	-1	730	5	732	3	824	12	806	7
MabThera/Rituxan	1,104	3	1,066	5	1,097	7	1,168	9	1,113	-1
Herceptin	766	11	711	11	703	0	791	3	718	-8
Perjeta	339	36	342	34	357	38	412	36	376	9
Ocrevus	496	163	560	82	581	59	715	54	741	46
Actemra/RoActemra	219	17	212	8	234	17	212	5	248	11
Xolair	486	14	498	9	486	12	469	1	503	2
Lucentis	425	27	413	2	428	47	457	11	471	9
Tecentriq	112	-7	110	-4	140	21	216	91	292	158
Activase/TNKase	315	11	303	1	302	4	351	7	310	-4
Kadcyla	92	12	91	6	90	1	125	39	153	62
Hemlibra	28	-	32	-	76	*	166	*	215	*
Esbriet	180	12	200	21	219	33	174	7	200	9
Alecensa	77	107	71	56	80	44	67	14	82	5
Pulmozyme	133	7	125	2	142	4	119	6	134	-1
CellCept	29	-14	32	16	21	-24	21	-20	22	-25
Mircera	-	-	-	-	-	-	-	-	-	-
Gazyva	50	29	52	24	50	25	55	22	55	8
Tamiflu	3	-100	3	-86	1	-100	24	-86	7	*
Xeloda	9	-54	9	50	9	183	9	10	6	-41

\* Over 500%



8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018
Avastin	464	-1	437	-1	450	1	461	1	459	3
MabThera/Rituxan	243	-50	206	-49	185	-46	171	-38	152	-35
Herceptin	525	-7	419	-21	354	-34	300	-44	268	-47
Perjeta	223	8	233	15	244	25	267	27	274	28
Ocrevus	50	*	52	*	76	*	92	232	119	149
Actemra/RoActemra	175	2	176	11	178	8	174	4	181	8
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Tecentriq	37	*	46	*	46	286	57	158	77	112
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Kadcyla	94	1	94	7	96	9	97	9	107	18
Hemlibra	2	-	15	-	20	*	26	450	37	*
Esbriet	58	19	55	15	61	14	62	14	66	18
Alecensa	20	349	23	137	39	217	46	182	50	154
Pulmozyme	34	5	32	8	34	8	35	8	33	3
CellCept	46	-4	44	-1	45	0	44	2	43	-2
Mircera	20	-17	19	-7	18	-8	17	-11	17	-7
Gazyva	34	66	36	79	37	52	38	31	42	31
Tamiflu	1	117	0	-33	3	-77	28	38	13	*
Xeloda	4	-33	4	-52	4	-27	4	-13	4	0

\* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018
Avastin	220	4	213	2	230	2	194	2	230	4
MabThera/Rituxan	51	-33	46	-40	37	-54	28	-50	30	-42
Herceptin	64	-19	60	-19	66	-17	56	-9	67	6
Perjeta	35	12	34	12	46	35	51	74	69	99
Ocrevus	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	91	18	91	16	99	13	86	13	102	11
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Tecentriq	15	-	29	-	37	-	33	-	42	169
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Kadcyla	19	12	20	8	20	3	18	12	22	11
Hemlibra	4	-	9	-	13	-	25	-	57	*
Esbriet	-	-	-	-	-	-	-	-	-	-
Alecensa	49	36	49	26	53	20	47	24	58	16
Pulmozyme	0	7	0	32	1	26	0	43	0	38
CellCept	21	3	20	0	22	-4	19	8	23	7
Mircera	52	-5	52	-4	58	-4	45	3	55	4
Gazyva	-	-	5	-	8	-	8	-	13	-
Tamiflu	1	-96	4	-77	16	-73	71	-6	1	153
Xeloda	30	6	27	5	30	1	22	-14	21	-30

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\*

CHF millions	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018
Avastin	351	9	310	21	329	15	319	16	366	10
MabThera/Rituxan	343	4	338	18	323	12	327	-4	350	8
Herceptin	495	4	493	13	552	32	519	26	545	17
Perjeta	103	56	90	42	114	46	138	83	168	73
Ocrevus	15	**	21	**	23	459	29	261	39	173
Actemra/RoActemra	65	25	50	-4	71	24	62	10	70	15
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Tecentriq	17	434	19	**	25	458	30	262	35	127
Activase/TNKase	14	4	14	-1	13	3	11	-10	14	6
Kadcyla	44	35	39	13	45	14	51	32	63	62
Hemlibra	-	-	-	-	2	-	2	-	7	-
Esbriet	12	43	12	40	12	-5	14	37	16	49
Alecensa	14	403	15	289	28	343	36	278	35	177
Pulmozyme	21	4	23	-11	25	-8	28	4	22	0
CellCept	79	-1	79	4	73	-11	79	13	74	-1
Mircera	56	25	79	44	58	-3	80	35	68	21
Gazyva	9	10	11	58	14	24	14	31	16	101
Tamiflu	23	-59	6	-4	25	11	56	55	27	30
Xeloda	71	-3	70	-3	58	-17	73	13	77	15

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

## 11. Roche Group consolidated income statement for the six months ended 30 June 2019

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
<b>Sales</b>	<b>24,194</b>	<b>6,275</b>	-	<b>30,469</b>
Royalties and other operating income	1,249	33	-	1,282
Cost of sales	(5,597)	(3,053)	-	(8,650)
Marketing and distribution	(3,464)	(1,442)	-	(4,906)
Research and development	(5,372)	(750)	-	(6,122)
General and administration	(842)	(104)	(286)	(1,232)
<b>Operating profit</b>	<b>10,168</b>	<b>959</b>	<b>(286)</b>	<b>10,841</b>
Financing costs				(414)
Other financial income (expense)				(73)
<b>Profit before taxes</b>				<b>10,354</b>
Income taxes				(1,450)
<b>Net income</b>				<b>8,904</b>
Attributable to				
- Roche shareholders				8,619
- Non-controlling interests				285
<b>Earnings per share and non-voting equity security</b>				
Basic (CHF)				10.07
Diluted (CHF)				9.99

## 12. Roche Group core results reconciliation – Half Year 2019

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
<b>Sales</b>	<b>30,469</b>	-	-	-	-	-	-	-	-	<b>30,469</b>
Royalties and other operating income	1,282	-	-	-	-	-	-	-	-	1,282
Cost of sales	(8,650)	171	611	-	-	-	-	-	-	(7,868)
Marketing and distribution	(4,906)	85	21	-	-	-	-	-	-	(4,800)
Research and development	(6,122)	132	105	324	-	-	-	-	-	(5,561)
General and administration	(1,232)	89	-	-	(84)	68	-	-	-	(1,159)
<b>Operating profit</b>	<b>10,841</b>	<b>477</b>	<b>737</b>	<b>324</b>	<b>(84)</b>	<b>68</b>	-	-	-	<b>12,363</b>
Financing costs	(414)	1	-	-	6	4	-	-	-	(403)
Other financial income (expense)	(73)	-	-	-	-	-	-	-	-	(73)
<b>Profit before taxes</b>	<b>10,354</b>	<b>478</b>	<b>737</b>	<b>324</b>	<b>(78)</b>	<b>72</b>	-	-	-	<b>11,887</b>
Income taxes	(1,450)	(95)	(78)	(37)	(12)	(6)	-	(235)	(78)	(1,991)
<b>Net income</b>	<b>8,904</b>	<b>383</b>	<b>659</b>	<b>287</b>	<b>(90)</b>	<b>66</b>	-	<b>(235)</b>	<b>(78)</b>	<b>9,896</b>
Attributable to										
- Roche shareholders	8,619	369	657	287	(90)	66	-	(235)	(78)	9,595
- Non-controlling interests	285	14	2	-	-	-	-	-	-	301
EPS - diluted (CHF)	9.99	0.43	0.75	0.34	(0.11)	0.08	-	(0.27)	(0.09)	11.12

### 13. Divisional core results reconciliation – Half Year 2019

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
<b>Pharmaceuticals</b>								
Sales	24,194	-	-	-	-	-	-	24,194
Royalties and other operating income	1,249	-	-	-	-	-	-	1,249
Cost of sales	(5,597)	103	555	-	-	-	-	(4,939)
Marketing and distribution	(3,464)	52	17	-	-	-	-	(3,395)
Research and development	(5,372)	73	102	324	-	-	-	(4,873)
General and administration	(842)	19	-	-	40	47	-	(736)
<b>Operating profit</b>	<b>10,168</b>	<b>247</b>	<b>674</b>	<b>324</b>	<b>40</b>	<b>47</b>	<b>-</b>	<b>11,500</b>
<b>Diagnostics</b>								
Sales	6,275	-	-	-	-	-	-	6,275
Royalties and other operating income	33	-	-	-	-	-	-	33
Cost of sales	(3,053)	68	56	-	-	-	-	(2,929)
Marketing and distribution	(1,442)	33	4	-	-	-	-	(1,405)
Research and development	(750)	59	3	-	-	-	-	(688)
General and administration	(104)	(5)	-	-	(124)	11	-	(222)
<b>Operating profit</b>	<b>959</b>	<b>155</b>	<b>63</b>	<b>-</b>	<b>(124)</b>	<b>11</b>	<b>-</b>	<b>1,064</b>
<b>Corporate</b>								
General and administration	(286)	75	-	-	-	10	-	(201)
<b>Operating profit</b>	<b>(286)</b>	<b>75</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>10</b>	<b>-</b>	<b>(201)</b>

## 14. Roche Group consolidated balance sheet

in millions of CHF	30 June 2019	31 December 2018	31 December 2017
<b>Non-current assets</b>			
Property, plant and equipment	22,065	21,818	20,912
Right-of-use assets	1,098	-	-
Goodwill	8,878	8,948	10,077
Intangible assets	9,078	9,346	8,368
Deferred tax assets	4,568	3,895	3,576
Defined benefit plan assets	887	877	801
Other non-current assets	1,305	1,389	1,370
<b>Total non-current assets</b>	<b>47,879</b>	<b>46,273</b>	<b>45,104</b>
<b>Current assets</b>			
Inventories	6,574	6,621	7,407
Accounts receivable	11,760	9,776	9,577
Current income tax assets	191	208	348
Other current assets	2,618	2,521	2,243
Marketable securities	5,483	6,437	7,278
Cash and cash equivalents	5,689	6,681	4,719
<b>Total current assets</b>	<b>32,315</b>	<b>32,244</b>	<b>31,572</b>
<b>Total assets</b>	<b>80,194</b>	<b>78,517</b>	<b>76,676</b>
<b>Non-current liabilities</b>			
Long-term debt	(15,398)	(16,077)	(15,839)
Net deferred tax liabilities	(246)	(384)	(495)
Defined benefit plan liabilities	(7,697)	(7,017)	(7,421)
Provisions	(1,415)	(1,452)	(1,548)
Other non-current liabilities	(976)	(188)	(206)
<b>Total non-current liabilities</b>	<b>(25,732)</b>	<b>(25,118)</b>	<b>(25,509)</b>
<b>Current liabilities</b>			
Short-term debt	(4,173)	(2,693)	(3,121)
Current income tax liabilities	(3,901)	(3,808)	(3,408)
Provisions	(2,193)	(2,329)	(2,042)
Accounts payable	(3,250)	(3,526)	(3,454)
Other current liabilities	(9,929)	(10,677)	(10,135)
<b>Total current liabilities</b>	<b>(23,446)</b>	<b>(23,033)</b>	<b>(22,160)</b>
<b>Total liabilities</b>	<b>(49,178)</b>	<b>(48,151)</b>	<b>(47,669)</b>
<b>Total net assets</b>	<b>31,016</b>	<b>30,366</b>	<b>29,007</b>
<b>Equity</b>			
Capital and reserves attributable to Roche shareholders	28,059	27,622	26,441
Equity attributable to non-controlling interests	2,957	2,744	2,566
<b>Total equity</b>	<b>31,016</b>	<b>30,366</b>	<b>29,007</b>

## 15. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2019	HY 2018
<b>Cash flows from operating activities</b>		
Cash generated from operations	14,092	12,711
(Increase) decrease in net working capital	(3,723)	(2,388)
Payments made for defined benefit plans	(294)	(358)
Utilisation of provisions	(485)	(364)
Disposal of products	436	307
Other operating cash flows	-	-
<b>Cash flows from operating activities, before income taxes paid</b>	<b>10,026</b>	<b>9,908</b>
Income taxes paid	(1,911)	(1,848)
<b>Total cash flows from operating activities</b>	<b>8,115</b>	<b>8,060</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(1,508)	(1,713)
Purchase of intangible assets	(914)	(259)
Disposal of property, plant and equipment	33	20
Disposal of intangible assets	-	-
Business combinations	(99)	(3,223)
Divestment of subsidiaries	2	-
Interest and dividends received	26	9
Sales of marketable securities	531	389
Purchases of marketable securities	(123)	(297)
Sales (purchases) of money market instruments and time accounts over three months, net	556	3,582
Other investing cash flows	(12)	184
<b>Total cash flows from investing activities</b>	<b>(1,508)</b>	<b>(1,308)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issue of bonds and notes	-	-
Redemption and repurchase of bonds and notes	-	(1,152)
Increase (decrease) in commercial paper	741	2,545
Increase (decrease) in other debt	206	151
Hedging and collateral arrangements	(16)	24
Changes in ownership interests in subsidiaries	(21)	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	13	-
Interest paid	(358)	(348)
Principal portion of lease liabilities paid	(178)	-
Dividends paid	(7,574)	(7,178)
Equity-settled equity compensation plans, net of transactions in own equity	(401)	(202)
Other financing cash flows	-	1
<b>Total cash flows from financing activities</b>	<b>(7,588)</b>	<b>(6,159)</b>
Net effect of currency translation on cash and cash equivalents	(11)	(19)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>(992)</b>	<b>574</b>
Cash and cash equivalents at beginning of period	6,681	4,719
<b>Cash and cash equivalents at end of period</b>	<b>5,689</b>	<b>5,293</b>